Navigation Links
febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment
Date:6/29/2009

febit Technology Enables the Conversion of New Sequence Data into Biochips for Gene Expression Profiling and Sequence Capture for Next-Generation Sequencing Within Days

LEXINGTON, Mass. and HEIDELBERG, Germany, June 29 /PRNewswire/ -- febit holding gmbh announced today the launch of the first biochip on the market covering the newly published whole mouse genome. The biochip from febit enables up-to-date profiling and enrichment of genes and SNPs of interest using Gene Expression Profiling, SNP-Detection, ncRNA analysis as well as targeted enrichment of genes for Next-Generation Sequencing (NGS).

Professor Christian Koerner from the University Hospital for Pediatrics in Heidelberg (Germany) and customer of febit's new mouse biochip, said: "It will be helpful and an advance for our research to use a whole genome microarray based on the most recent data available which have been published only weeks ago. This array allows the performance of a microarray expression profiling as well as a targeted Next-Generation Sequencing at the current state of the art."

In the near future, Next-Generation Sequencing technologies will lead to a rising number of completed genomes of model organisms and other species of interest, as demonstrated by the updated mouse genome. This accelerated development will generate a variety of tools available in the short term for the application of the new data into experiments. febit's Geniom(R) Technology represents the most efficient option for transforming digital genetic sequence information directly into a fully-applicable microarray and sequence capture biochip. The microfluidic biochips and flexible probe synthesis guarantee instant access to the latest sequence updates within only days after publication or request.

New mouse genome assembly

The mouse (mus musculus) is the most important and well-established model for the study of human disease and mammalian development. At the end of May 2009, D.M. Church et al. published in the journal PLoS Biology a complete, high-quality genome assembly that contains over 139 Mb more of novel sequence compared to previously available mouse genome drafts. This brand-new, finished mouse genome, which is now available on febit's microarrays, closes more than 175,000 gaps, completes the list of protein-coding genes to a number of 20,210 and identifies 439 long, non-coding RNAs. Thus, a complete analysis of protein gene expression, microRNA profiles and expression patterns of long non-coding RNAs is possible and can reveal many previously hidden secrets of mammalian biology and disease processes.

Flexibel technology for fast-paced research

febit's Geniom Technology provides turnkey solutions with established protocols and streamlined workflows, enabling all major RNA profiling applications as well as targeted Next-Generation Sequencing. HybSelect, sequence-specific DNA enrichment is enabled through hybridization and elution of high-value target regions by utilizing febit's flexible Geniom Biochips. The enriched DNA is ideally suited for cost-effective targeted sequencing on Next-Generation Sequencing platforms. With its new HybSelect Biochip for the mouse genome, febit complements its offering for up-to-date sequence analyses in the field of mammalian research. Biochips for other models will follow as soon as the appropriate sequence analyses are completed. febit biochips are available for analysis at the Geniom RT Analyzer or as a full service from febit.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

For its main applications - HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing and protein-coding or non-coding transcriptome profiling - the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.

For more information, please visit www.febit.com.

    Contact:
    febit group, Eva Sterzel, eva.sterzel@febit .com, +49 (0)6221 6510-300

    Russo Partners, Martina Schwarzkopf,
    martina.schwarzkopf@russopartnersllc.com, +1 212 845-4292


'/>"/>
SOURCE febit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Paul Keim Appointed to febits Scientific Advisory Board
2. febit Receives U.S. Patent for Microfluidic Extraction Method
3. febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
4. febit First to Offer miRBase 11.0 Biochip
5. febit Forms Scientific Advisory Board
6. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
7. Scientists create first electronic quantum processor
8. Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training
9. First-Ever Egg Donor Web Portal Becomes One of The Largest Resources for Aspiring Parents in the U.S.
10. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
11. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... 4, 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today provided an update on ... Northern District of Texas and ... Inter Partes Re-examination ("IPR") proceedings that VTech ... IPR was initiated on only certain claims of two ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
Breaking Biology News(10 mins):